# Alpha Tau to Participate in September Investor Conferences
Canonical URL: https://biopharmsignal.com/news/DRTS/alpha-tau-to-participate-in-september-investor-conferences-b396a38a
Ticker: DRTS
Company: Alpha Tau Medical
Source: Alpha Tau Medical
Published: 2026-09-02 12:00 EST
## Summary

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today an...

## Article Body
Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will participate in the following investor conferences in September 2026.

| Event: | Citi's 2026 Biopharma Back to School Conference |
| --- | --- |
| Format: | 1x1 Meetings |
| Date: | Wednesday, September 9, 2026 |
| Location: | New York, NY |

| Event: | H.C. Wainwright 28 th Annual Global Investor Conference |
| --- | --- |
| Format: | Fireside Chat and 1x1 Meetings |
| Date: | Monday, September 14, 2026 |
| Time: | 9:30 – 10:00AM ET |
| Location: | New York, NY |

Mr. Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your Citi or H.C. Wainwright representatives to schedule.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT ®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact:

IR@alphatau.com
## Recent Company News
- 2026-09-02 12:00 EST — [Alpha Tau to Participate in September Investor Conferences](https://biopharmsignal.com/news/DRTS/alpha-tau-to-participate-in-september-investor-conferences-b396a38a) — Source: Alpha Tau Medical
- 2026-08-31 12:00 EST — [Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions](https://biopharmsignal.com/news/DRTS/alpha-tau-completes-patient-enrollment-in-its-multicenter-impact-pancreatic-canc-b5340ad9) — Source: Alpha Tau Medical
- 2026-08-10 20:01 EST — [Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/DRTS/alpha-tau-announces-second-quarter-2026-financial-results-and-provides-corporate-0644bab3) — Source: Alpha Tau Medical
- 2026-08-10 12:00 EST — [Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)](https://biopharmsignal.com/news/DRTS/alpha-tau-registers-for-dual-listing-on-the-tel-aviv-stock-exchange-tase-737b9400) — Source: Alpha Tau Medical
- 2026-07-21 12:30 EST — [Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success](https://biopharmsignal.com/news/DRTS/alpha-tau-reports-positive-data-demonstrating-100-objective-response-rate-and-18-ca86b4f0) — Source: Alpha Tau Medical
## Related News
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)